NASDAQ:DCTH Delcath Systems (DCTH) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free DCTH Stock Alerts $4.77 -0.32 (-6.29%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$4.76▼$5.0550-Day Range$3.72▼$5.0952-Week Range$2.25▼$7.99Volume393,065 shsAverage Volume246,003 shsMarket Capitalization$117.15 millionP/E RatioN/ADividend YieldN/APrice Target$18.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Delcath Systems alerts: Email Address Delcath Systems MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside287.8% Upside$18.50 Price TargetShort InterestHealthy4.08% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 17 Articles This WeekInsider TradingAcquiring Shares$100,001 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.90) to ($1.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.48 out of 5 starsMedical Sector310th out of 938 stocksSurgical & Medical Instruments Industry39th out of 95 stocks 3.5 Analyst's Opinion Consensus RatingDelcath Systems has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.50, Delcath Systems has a forecasted upside of 287.8% from its current price of $4.77.Amount of Analyst CoverageDelcath Systems has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.08% of the outstanding shares of Delcath Systems have been sold short.Short Interest Ratio / Days to CoverDelcath Systems has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Delcath Systems has recently increased by 7.95%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDelcath Systems does not currently pay a dividend.Dividend GrowthDelcath Systems does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DCTH. Previous Next 2.4 News and Social Media Coverage News SentimentDelcath Systems has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Delcath Systems this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for DCTH on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added Delcath Systems to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Delcath Systems insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,001.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders21.10% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.12% of the stock of Delcath Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Delcath Systems are expected to grow in the coming year, from ($1.90) to ($1.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Delcath Systems is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Delcath Systems is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Delcath Systems Stock (NASDAQ:DCTH)Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Read More DCTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DCTH Stock News HeadlinesMarch 21, 2024 | insidertrades.comInsider Buying: Delcath Systems, Inc. (NASDAQ:DCTH) Director Acquires 26,882 Shares of StockMarch 28, 2024 | americanbankingnews.comDelcath Systems (NASDAQ:DCTH) Price Target Increased to $20.00 by Analysts at HC WainwrightMarch 29, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.March 28, 2024 | americanbankingnews.comDelcath Systems (NASDAQ:DCTH) Upgraded to "Sell" at StockNews.comMarch 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), Zevra Therapeutics (ZVRA) and Corcept Therapeutics (CORT)March 27, 2024 | finance.yahoo.comDelcath Systems, Inc. (NASDAQ:DCTH) Q4 2023 Earnings Call TranscriptMarch 26, 2024 | finance.yahoo.comDelcath Systems Inc (DCTH) Reports Mixed Year-End Financials Amidst Strategic AdvancementsMarch 26, 2024 | finanznachrichten.deDelcath Systems, Inc.: Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateMarch 29, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 26, 2024 | msn.comDelcath Systems GAAP EPS of -$0.48, revenue of $0.54MMarch 26, 2024 | prnewswire.comDelcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateMarch 25, 2024 | msn.comDelcath Systems Q4 2023 Earnings PreviewMarch 24, 2024 | americanbankingnews.comDelcath Systems (DCTH) Scheduled to Post Quarterly Earnings on TuesdayMarch 23, 2024 | finance.yahoo.comInsiders of Delcath Systems Getting Good Value On Their US$736.5k InvestmentMarch 20, 2024 | prnewswire.comDelcath Systems Closes $7 Million Private PlacementMarch 19, 2024 | prnewswire.comDelcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update CallMarch 19, 2024 | finanznachrichten.deDelcath Systems, Inc.: Delcath Systems Appoints Martha S. Rook as Chief Operating OfficerMarch 18, 2024 | markets.businessinsider.comDelcath Systems Appoints Martha Rook As COOMarch 18, 2024 | prnewswire.comDelcath Systems Appoints Martha S. Rook as Chief Operating OfficerMarch 17, 2024 | investing.comDelcath Systems secures $7 million in private placementMarch 16, 2024 | finance.yahoo.comDCTH Apr 2024 7.500 callMarch 15, 2024 | markets.businessinsider.comDelcath Announces $7 Mln Private PlacementMarch 15, 2024 | prnewswire.comDelcath Systems Announces $7 Million Private PlacementMarch 8, 2024 | prnewswire.comDelcath Systems to Participate in Upcoming Investor ConferencesFebruary 22, 2024 | stockhouse.comDelcath Systems Announces Healthcare Setting Locator for HEPZATO(TM) KIT (melphalan/Hepatic Delivery System)February 22, 2024 | finance.yahoo.comDelcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)February 16, 2024 | prnewswire.comDelcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive DCTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today3/29/2024Next Earnings (Estimated)5/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:DCTH CUSIPN/A CIK872912 Webdelcath.com Phone212-489-2100Fax212-489-2102Employees52Year FoundedN/APrice Target and Rating Average Stock Price Target$18.50 High Stock Price Target$21.00 Low Stock Price Target$13.00 Potential Upside/Downside+287.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,510,000.00 Net Margins-2,308.86% Pretax Margin-2,079.17% Return on Equity-1,007.65% Return on Assets-115.78% Debt Debt-to-Equity Ratio0.08 Current Ratio3.30 Quick Ratio3.11 Sales & Book Value Annual Sales$2.07 million Price / Sales50.81 Cash FlowN/A Price / Cash FlowN/A Book Value($0.58) per share Price / Book-8.22Miscellaneous Outstanding Shares22,050,000Free Float17,394,000Market Cap$105.18 million OptionableOptionable Beta0.51 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Gerard J. Michel MBA (Age 61)MS, CEO & Director Comp: $671.6kMr. John Purpura M.S. (Age 63)Chief Operating Officer Comp: $485.92kDr. Johnny John M.D. (Age 60)Senior Vice President Clinical Development & Medical Affairs Comp: $472.16kMs. Sandra Pennell (Age 45)Senior VP of Finance and Principal Financial & Accounting Officer Mr. David HoffmanGeneral Counsel, Corporate Secretary & Chief Compliance OfficerDr. Vojislav Vukovic M.D. (Age 57)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsKORU Medical SystemsNASDAQ:KRMDBlueRiver AcquisitionNYSE:BLUABrainsWayNASDAQ:BWAYAllurion TechnologiesNYSE:ALURenVVeno MedicalNASDAQ:NVNOView All CompetitorsInsiders & InstitutionsGil AharonBought 26,882 shares on 3/19/2024Total: $100,001.04 ($3.72/share)Vanguard Group Inc.Bought 85,948 shares on 3/11/2024Ownership: 2.367%Vanguard Group Inc.Bought 85,948 shares on 2/15/2024Ownership: 2.368%Citadel Advisors LLCBought 18,300 shares on 2/15/2024Ownership: 0.000%ADAR1 Capital Management LLCBought 231,302 shares on 2/14/2024Ownership: 1.049%View All Insider TransactionsView All Institutional Transactions DCTH Stock Analysis - Frequently Asked Questions Should I buy or sell Delcath Systems stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DCTH shares. View DCTH analyst ratings or view top-rated stocks. What is Delcath Systems' stock price target for 2024? 4 Wall Street analysts have issued 1-year target prices for Delcath Systems' shares. Their DCTH share price targets range from $13.00 to $21.00. On average, they anticipate the company's share price to reach $18.50 in the next year. This suggests a possible upside of 287.8% from the stock's current price. View analysts price targets for DCTH or view top-rated stocks among Wall Street analysts. How have DCTH shares performed in 2024? Delcath Systems' stock was trading at $4.16 at the beginning of 2024. Since then, DCTH stock has increased by 14.7% and is now trading at $4.77. View the best growth stocks for 2024 here. Are investors shorting Delcath Systems? Delcath Systems saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 898,900 shares, an increase of 8.0% from the February 29th total of 832,700 shares. Based on an average daily trading volume, of 235,400 shares, the short-interest ratio is currently 3.8 days. View Delcath Systems' Short Interest. When is Delcath Systems' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024. View our DCTH earnings forecast. How were Delcath Systems' earnings last quarter? Delcath Systems, Inc. (NASDAQ:DCTH) issued its earnings results on Tuesday, March, 26th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.19. The firm earned $0.54 million during the quarter, compared to analyst estimates of $0.48 million. Delcath Systems had a negative net margin of 2,308.86% and a negative trailing twelve-month return on equity of 1,007.65%. During the same quarter in the prior year, the business earned ($0.86) EPS. When did Delcath Systems' stock split? Delcath Systems shares reverse split on the morning of Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are Delcath Systems' major shareholders? Delcath Systems' stock is owned by many different retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (5.36%), Vivo Capital LLC (3.88%), Vanguard Group Inc. (2.37%), Vanguard Group Inc. (2.37%), Worth Venture Partners LLC (1.33%) and ADAR1 Capital Management LLC (1.05%). Insiders that own company stock include Ernest C Garcia II, Gerard J Michel, Gil Aharon, John Purpura, John Richard Sylvester, Rosalind Advisors, Inc, Sandra Pennell, Steven A J Salamon and Vojo Vukovic. View institutional ownership trends. How do I buy shares of Delcath Systems? Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DCTH) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.